RT Journal Article
SR Electronic
T1 Ad-hoc Assembly of Lean Extracorporeal Membrane Oxygenation Systems for COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.12.20061929
DO 10.1101/2020.04.12.20061929
A1 Patrick Hunziker
A1 Urs Zenklusen
YR 2020
UL http://medrxiv.org/content/early/2020/04/17/2020.04.12.20061929.abstract
AB Background The COVID-19 epidemic is overwhelming intensive care units with bilateral pneumonia patients requiring respiratory assistance. Bottlenecks in availability of ventilators and extracorporeal membrane oxygenation may contribute to mortality, implying ethically difficult rationing decisions. It is unclear if accelerated equipment production will meet demand, calling for fallback solutions for life support in worst-case scenarios.Methods Veno-venous extracorporeal gas exchange (VV-ECMO) can provide vital support in bilateral lung failure. VV-ECMO essentially comprises large flow venous accesses, membrane gas exchange, and a blood pump. As thousands of FDA and CE certified Impella blood pumps and consoles are distributed globally for cardiac support, we explored ad-hoc assembly of lean ECMO systems by embedding Impella pumps coaxially in tubes in combination with standard gas exchangers.Results Ad-hoc integration of Impella blood pumps with gas exchange modules, standard cannulas for large bore venous access, regular ECMO tubing, Y-pieces and connectors led to lean ECMO systems with stable performance over several days. Oxygenation of 2.5-5 L of blood/minute is realistic. Benefit/risk analysis appears favorable if a patient requires respiratory support but cannot be supported because of lack of ventilators or unavailability of a required ECMO system.Conclusion Ad-hoc assembly of veno-venous ECMOs using Impella pumps is feasible and results in stable blood flow across gas exchange modules. However, such off-label use of the devices calls for specific ethical and regulatory considerations prior to their use as last resort in patients for whom no other treatment modalities are available.Competing Interest StatementPH is inventor patents in cardiovascular support and monitoring, has received speakers fees and research grants by various funding professional societies, funding agencies and companies including Abiomed, not related to this manuscript submission.Funding StatementNo external funding, services or payments received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are given in supplement.